3results about How to "Blocking interaction" patented technology

The invention discloses an application of an IGF2BP1 fragment in preparation of an inhibition tool for screening and blocking the interaction between IGF2BP1 and SOX2 protein, and the IGF2BP1 fragment is an amino acid sequence from 161st to 578th of the IGF2BP1, and is shown as SEQ ID NO.01. The invention also discloses an application of the IGF2BP1 fragment in preparation of an inhibition tool for screening and blocking the interaction between IGF2BP1 and SOX2 protein. According to the present invention, the 161-578 amino acid fragment (IGF2BP1 [delta] C (161-578)) of the IGF2BP1 protein is the minimum functional structure domain of the IGF2BP1 protein directly interacting with the SOX2 protein, and the fragment sequence provides the clear targeting site for the subsequent accurate blocking of the IGF2BP1-SOX2 interaction through the dual verification of the bimolecular fluorescence complementation and the co-immunoprecipitation;

The invention belongs to the technical field of fusion proteins, and particularly relates to an anti-TIGIT / rhIL-21 bifunctional fusion protein and application thereof. According to the anti-TIGIT / rhIL-21 bifunctional fusion protein provided by the invention, the Fc segment is combined with the rhIL-21, so that the in-vivo stability of the IL-21 is remarkably enhanced, the half-life period of the IL-21 is successfully prolonged, the limitation that the half-life period of the rhIL-21 is short when the rhIL-21 is independently used is overcome, and a powerful guarantee is provided for continuous treatment. According to the anti-TIGIT / rhIL-21 bifunctional fusion protein provided by the invention, the antibody aiming at TIGIT and the recombinant human interleukin-21 are ingeniously fused, so that effective blocking of immune checkpoints and efficient activation of immune cells are synchronously carried out, the in-vivo pharmacokinetic characteristics of IL-21 are optimized, and the anti-TIGIT / rhIL-21 bifunctional fusion protein has the advantages that the anti-TIGIT / rhIL-21 bifunctional fusion protein can be used for preparing anti-TIGIT antibodies. And mobilization and function enhancement of immune cells are greatly promoted, an innovative strategy is provided for solving the problem of cold tumors and improving the immunotherapy effect, and wide application prospects are shown.

This invention discloses a PBP peptide that specifically binds to PD-1, its screening method, and its applications. The PBP peptide has the sequence shown in SEQ ID No. 1. This invention uses bacterial surface display technology to screen for PD-1-targeting PBP peptides. These peptides specifically bind to PD-1, exhibit cross-reactivity with human and mouse PD-1, and can competitively bind to PD-1 with PD-L1, effectively blocking the interaction between PD-1 and PD-L1, reversing the function of exhausted T cells, and exerting an anti-tumor effect. Compared to antibodies, the PBP peptide obtained in this invention has a small molecular weight, strong penetration ability at tumor sites, low production cost, simple preparation process, and does not cause serious immune-related side effects. While achieving corresponding therapeutic effects, it avoids the disadvantages of antibody drugs, providing a low-molecular-weight candidate drug for tumor immunotherapy.